The ASCO Post

The ASCO Post News and views from the world of clinical oncology and hematology

THE ASCO POST delivers timely and unbiased reports on major oncology meetings across the globe, including ASCO's annual meeting and regional symposia. Additionally, this newspaper-style publication provides readers with important summaries of evidence-based clinical literature from both general and specialty journals (fully sourced with links to original reports); notable research, data, and liter

ature with application in the clinic, including cost considerations/implications; columns from ASCO's membership with perspective on developments in oncology, quality cancer care, technology, electronic health records, and expert opinion on the state and economics of cancer care.

Alcohol May Be Linked to Higher Risk of Pancreatic Cancer
07/07/2025

Alcohol May Be Linked to Higher Risk of Pancreatic Cancer

Investigators have examined the association between alcohol consumption and the risk of developing pancreatic cancer.

HER3‑DXd in NSCLC Without EGFR‑Activating Mutations
07/04/2025

HER3‑DXd in NSCLC Without EGFR‑Activating Mutations

As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd...

Harm Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non Small Cell Lung Cancer
07/02/2025

Harm Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non Small Cell Lung Cancer


In a study reported in JAMA Oncology, Heyward et al examined the harm-benefit balance of immune checkpoint inhibitor use across lines of treatment in non–small cell lung cancer.

Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer
06/30/2025

Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standar...

Dose Escalated Stereotactic Body Radiotherapy vs Conventional Radiotherapy for Painful Bone Metastases
06/25/2025

Dose Escalated Stereotactic Body Radiotherapy vs Conventional Radiotherapy for Painful Bone Metastases

In a Belgian phase III trial (ROBOMET) reported in the Journal of Clinical Oncology, Mercier et al attempted to determine whether dose-escalated, single-fraction stereotactic body radiotherapy was ass...

FDA Grants Accelerated Approval to Datopotamab Deruxtecan for EGFR-Mutated NSCLC
06/24/2025

FDA Grants Accelerated Approval to Datopotamab Deruxtecan for EGFR-Mutated NSCLC

The FDA approved the agent for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.

06/20/2025

Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd Preside...

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Cancer
06/20/2025

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Cancer

The FDA approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [combined positive score ≥ 1] as determined by a...

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma
06/18/2025

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneou...

Revumenib Triplet Regimen Shows Promise in NPM1-Mutant and KMT2A-Rearranged AML
06/17/2025

Revumenib Triplet Regimen Shows Promise in NPM1-Mutant and KMT2A-Rearranged AML

A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia and an NPM1 m...

Elinzanetant for Vasomotor Symptoms From Endocrine Therapy for Breast Cancer
06/13/2025

Elinzanetant for Vasomotor Symptoms From Endocrine Therapy for Breast Cancer

In a phase III trial (OASIS-4) reported at the 2025 Annual ASCO Meeting and in the New England Journal of Medicine, Cardoso et al attempted to determine whether the neurokinin-targeted therapy elinzan...

Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
06/11/2025

Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy

With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent o...

Address

Huntington, NY

Website

Alerts

Be the first to know and let us send you an email when The ASCO Post posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to The ASCO Post:

Shortcuts

Share

Category